Intensity Therapeutics
$5.72
46
+$0.03+0.54% Today
Statistics
Day High
5.99
Day Low
5.69
52W High
51.5
52W Low
5.59
Volume
15,372
Avg. Volume
53,021
Mkt Cap
343.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-1.27
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-32.54MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow INTS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Pfizer
PFE
Mkt Cap140.15B
Novartis
NVS
Mkt Cap237.61B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Astrazeneca
AZN
Mkt Cap256.58B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Johnson & Johnson
JNJ
Mkt Cap455.04B
About
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Show more...
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Employees
5
Country
US
ISIN
US45828J2024
Listings
0 Comments
Share your thoughts
FAQ
What is Intensity Therapeutics stock price today?▼
The current price of INTS is $5.72 USD — it has increased by +0.54% in the past 24 hours. Watch Intensity Therapeutics stock price performance more closely on the chart.
What is Intensity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Intensity Therapeutics stocks are traded under the ticker INTS.
Is Intensity Therapeutics stock price growing?▼
INTS stock has fallen by -6.38% compared to the previous week, the month change is a -24.54% fall, over the last year Intensity Therapeutics has showed a -88.56% decrease.
What is Intensity Therapeutics market cap?▼
Today Intensity Therapeutics has the market capitalization of 343.57M
When is the next Intensity Therapeutics earnings date?▼
Intensity Therapeutics is going to release the next earnings report on May 07, 2026.
What were Intensity Therapeutics earnings last quarter?▼
INTS earnings for the last quarter are -1.5 USD per share, whereas the estimation was -1.58 USD resulting in a +5.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Intensity Therapeutics revenue for the last year?▼
Intensity Therapeutics revenue for the last year amounts to 0 USD.
What is Intensity Therapeutics net income for the last year?▼
INTS net income for the last year is -32.54M USD.
How many employees does Intensity Therapeutics have?▼
As of April 02, 2026, the company has 5 employees.
In which sector is Intensity Therapeutics located?▼
Intensity Therapeutics operates in the Health Care sector.
When did Intensity Therapeutics complete a stock split?▼
The last stock split for Intensity Therapeutics was on February 19, 2026 with a ratio of 1:25.
Where is Intensity Therapeutics headquartered?▼
Intensity Therapeutics is headquartered in Shelton, US.